2021-000542-18: A Study to Investigate the Impact of Switching Between ABP 501 and Adalimumab for the Treatment of Subjects with Moderate to Severe Plaque Psoriasis |
|
|
| Not yet recruiting | 3 | 414 | Europe | ABP 501-HCF, Solution for injection in pre-filled syringe, Humira | Amgen Inc., Amgen Inc. | Moderate to Severe Plaque Psoriasis, Moderate to Severe Plaque Psoriasis, Diseases [C] - Immune System Diseases [C20] | | | | |
NCT04610476: Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis |
|
|
| Recruiting | 3 | 270 | Europe | Prednisolone, Prednisolone generic drugs, Sulfasalazine, Azulfidine, Leflunomide, Arava, Methotrexate, Lantarel, Metex, Tofacitinib, Xeljanz, Apremilast, Otezla, Etanercept, Enbrel, Erelzi, Benepali, Adalimumab, Humira, Amgevita, Imraldi, Hyrimoz, Infliximab, Remicade, Zessly, Inflectra, Certolizumab pegol, Cimzia, Golimumab, Simponi, Abatacept, Orencia, Secukinumab, Cosentyx, Ixekizumab, Taltz, Ustekinumab, Stelara | University of Erlangen-Nürnberg Medical School | Psoriatic Arthritis, Withdrawal, Reduction | 10/24 | 10/25 | | |
